MiNK Therapeutics, Inc. (INKT): Price and Financial Metrics
INKT Price/Volume Stats
| Current price | $0.90 | 52-week high | $3.34 |
| Prev. close | $0.87 | 52-week low | $0.75 |
| Day low | $0.86 | Volume | 31,273 |
| Day high | $0.90 | Avg. volume | 90,915 |
| 50-day MA | $0.96 | Dividend yield | N/A |
| 200-day MA | $1.18 | Market Cap | 31.18M |
INKT Stock Price Chart Interactive Chart >
MiNK Therapeutics, Inc. (INKT) Company Bio
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate includes AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Latest INKT News From Around the Web
Below are the latest news stories about MINK THERAPEUTICS INC that investors may wish to consider to help them evaluate INKT as an investment opportunity.
MiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial ChallengesKey Financial and Operational Highlights from MiNK Therapeutics' Third Quarter |
MiNK Therapeutics Reports Third Quarter 2023 ResultsMiNK presents first-of-a-kind data with allogeneic iNKTs, agenT-797, showing durable clinical benefit in solid tumor cancers and persistence >6 months without toxic pre-conditioning.AgenT-797 demonstrates potential beyond cancer, with improved survival in severe respiratory distress. MiNK plans for expansion in autoimmune and inflammatory diseases.Conference Call on Thursday, November 9, 2023, at 8:30 a.m. ET. NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a |
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023Clinical responses and durable activity with agenT-797 monotherapy and in combination with anti-PD-1First-of-a-kind persistence for an allogeneic cell therapy, with agenT-797 detected for up to 6 months without toxic pre-conditioningAgenT-797 advancing in a randomized phase 2 trial in 2L gastric cancer NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allog |
MiNK Therapeutics Insider Ups Holding During YearLooking at MiNK Therapeutics, Inc.'s ( NASDAQ:INKT ) insider transactions over the last year, we can see that insiders... |
MiNK to Provide Third Quarter 2023 Financial Report and Corporate UpdateNEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its third quarter 2023 financial results via press release before the market opens on Thursday, Nov. 9, 2023. About MiNK Therapeutics M |
INKT Price Returns
| 1-mo | 0.45% |
| 3-mo | 2.27% |
| 6-mo | -12.62% |
| 1-year | -55.22% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -15.89% |
| 2023 | -59.00% |
| 2022 | -41.48% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...